Skip to main content
MNPR
NASDAQ Life Sciences

Monopar Posts $6.2M Q3 Loss, $129.4M Cash, NDA Submission Weeks Away

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$70.3
Mkt Cap
$481.464M
52W Low
$50.07
52W High
$124.82
52W Position info
40% above low
Off High info
44% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MNPR sits 40% above its 52-week low of $50.07.

Summary

Monopar reported a $6.2 million third-quarter loss and $129.4 million in cash, enough to fund operations into 2028, while saying its rolling NDA submission for Wilson disease drug ALXN1840 should be complete within weeks.


Key Events · Earnings and Guidance · MNPR

  • Q3 Loss Widens on Launch Prep

    Net loss was $6.2 million, or $0.72 per share, versus $3.4 million, or $0.48 per share, a year earlier. R&D rose to $4,436,543 from $2,589,749, and G&A to $3,031,302 from $1,503,326.

  • Cash Funds Operations Into 2028

    Cash, cash equivalents and investments totaled $129.4 million at September 30, 2026, which the company expects to support operations through at least March 31, 2028.

  • ALXN1840 NDA Nears Completion

    The rolling NDA submission for ALXN1840 in Wilson disease, initiated July 22, 2026, is on track to be completed within the next several weeks. FDA acceptance and approval timing are not yet determined.

  • AASLD Data Show Residual Disease Burden

    Baseline FoCus Phase 3 findings presented November 8, 2026, showed 39% cirrhosis and 79% neurologic symptoms in treatment-experienced patients, with only 47% within the guideline copper target range.


Analysis · MNPR · Life Sciences

The quarter itself is unremarkable: the loss widened to $6.2 million from $3.4 million as R&D and G&A scaled up for a commercial launch. What matters is the balance sheet and the regulatory clock. With $129.4 million in cash, operations are funded through at least March 31, 2028, so there is no near-term financing need, and the rolling NDA for ALXN1840 in Wilson disease is expected to be complete within weeks. That filing is the binary event for this stock: acceptance and eventual approval of a first-in-class drug with no approved competitor in a rare disease. Against that, insiders have been steady sellers under pre-set 10b5-1 plans, which is worth noting but is programmatic rather than a change in conviction.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNPR was trading at $70.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $481.5M. The 52-week trading range was $50.07 to $124.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNPR - Latest Insights

MNPR
Nov 12, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $70.30 info
Change: $0 (0%) info
Market Cap: $481.464M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $115.19
Real-time Price: $70.30 info
Change: -$44.89 (-39%) info
Market Cap: $481.464M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $114.46
Real-time Price: $70.30 info
Change: -$44.16 (-39%) info
Market Cap: $481.464M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $115.19
Real-time Price: $70.30 info
Change: -$44.89 (-39%) info
Market Cap: $481.464M info
MNPR
Jul 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $113.57
Real-time Price: $70.30 info
Change: -$43.27 (-38%) info
Market Cap: $481.464M info